AI-generated research brief — verify at source
Sentinel Node Biopsy Linked to Significantly Reduced Melanoma Death Risk
A meta-analysis of 13 studies and more than 40,000 participants found that melanoma patients who underwent sentinel node biopsy had approximately 14% lower risk of dying from melanoma compared with those who did not (HR 0.86, 95% CI 0.81–0.92, p<0.0001). This result was robust across sensitivity analyses and showed low statistical heterogeneity, strengthening confidence in the observed association.
What Was Studied
This study investigated whether sentinel node biopsy (SNB) — a procedure used to stage cutaneous melanoma by sampling the first draining lymph node — confers a meaningful reduction in the risk of death from melanoma. Despite its widespread use, the survival benefit of SNB has remained contested, and this meta-analysis sought to resolve that uncertainty by pooling the best available comparative evidence.
How It Was Studied
Researchers conducted a pre-registered systematic review and meta-analysis, searching four major databases — Medline, Embase, Cochrane CENTRAL, and ClinicalTrials.gov — through January 2025. Eligible studies were those reporting survival outcomes in adults (aged 18 or older) with cutaneous melanoma who underwent SNB versus those who did not, and which provided sufficient data to calculate survival risk. From 1,560 screened records, 60 studies met inclusion criteria. For the primary adjusted-risk analysis, 13 studies involving 40,287 participants were included after one study was removed due to high selection bias. Duplicate title review and independent data extraction were performed, and risk of bias was assessed using established tools (Newcastle-Ottawa and Cochrane Collaboration scales).
What Was Observed
- Patients who underwent SNB had a statistically significant and meaningful reduction in melanoma-specific mortality — approximately 14% lower risk of dying from melanoma — compared with those who did not undergo the procedure (HR 0.86, 95% CI 0.81–0.92, p<0.0001). The narrow confidence interval indicates a precise estimate.
- The pooled result demonstrated low heterogeneity across the 13 included studies (I² reported as low), suggesting that the survival benefit was consistent rather than driven by variation between study populations or methodologies.
- SNB was also associated with a significantly reduced risk of disease recurrence, extending the observed benefit beyond overall survival to disease control more broadly.
- Sensitivity analyses confirmed the robustness of the primary finding, and the results were described as consistent with the only published randomised controlled trial in this area, providing convergent evidence from multiple study designs.
Why This Matters
The survival benefit of SNB has long been debated within the field of melanoma management, and this meta-analysis provides the most comprehensive quantitative synthesis to date, drawing on adjusted estimates from over 40,000 patients. The alignment of these observational findings with the existing randomised controlled trial strengthens the case that the observed benefit reflects a true causal effect rather than selection bias or confounding. Both survival and recurrence benefits were identified, suggesting that the clinical value of SNB extends across multiple outcome domains that matter to patients.
How to Read This Result
While the analysis is large and methodologically careful, the majority of included studies are observational in design, and even after adjustment for known confounders, residual bias from unmeasured patient or treatment factors cannot be entirely excluded.
Limitations
The abstract does not explicitly report study limitations beyond the exclusion of one study due to high selection bias. The reliance on adjusted observational data in most included studies means that confounding cannot be fully ruled out, and the completeness of survival data across all 60 eligible studies was not addressed.